Other Information
−Removed: During the three months ended March 31, 2025, none of our executive officers or directors adopted, terminated or modified a "Rule 10b5-1(c) trading arrangement" or a “non-Rule 10b5-1 trading arrangement” (as each term is defined in Item 408 of Regulation S-K), except as described below.
−Removed: On March 11, 2025 , Karl Dahlquist , our Chief Legal Officer , adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
−Removed: Dahlquist's plan covers the sale of up to 24,271 shares of our common stock between June 10, 2025 and June 30, 2026.
−Removed: Transactions under the plan were based upon pre-established dates and stock price thresholds.
−Removed: 10.1# Form of Performance Share Award Agreement for Awards Granted in 2025.
+Added: During the three months ended June 30, 2025, none of our executive officers or directors adopted, terminated or modified a "Rule 10b5-1(c) trading arrangement" or a “non-Rule 10b5-1 trading arrangement” (as each term is defined in Item 408 of Regulation S-K).
+Added: 10.1# AtriCure, Inc.
+Added: 2023 Stock Incentive Plan (Amended and Restated as of May 19, 2025) (incorporated by reference to our Current Report on Form 8-K filed on May 20, 2025).
31.1 Rule 13a-14(a) Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
15 unchanged sentences
AtriCure , Inc.
−Removed: April 30, 2025
+Added: July 30, 2025
/s/ Michael H.
1 unchanged sentence
(Principal Executive Officer)
−Removed: April 30, 2025
+Added: July 30, 2025
/s/ Angela L.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.